NCT05006794 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions

Solid Malignancies

Interventions

DRUG

zamzetoclax

Tablet(s) administered orally

DRUG

Docetaxel

Administered intravenously

DRUG

sacituzumab govitecan-hziy

Administered intravenously

Trial Locations (13)

10467

Montefiore Medial Center - Montefiore Medical Park, The Bronx

28204

Novant Health Cancer Institute - Elizabeth (Breast Cancer), Charlotte

31096

Rambam Health Care Campus, Haifa

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

49546

START Midwest, Grand Rapids

73104

Stephenson Cancer Center, Oklahoma City

78229

START San Antonio, San Antonio

80045

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora

84119

START Mountain Region, West Valley City

91120

Hadassah Medical Center- Ein Kerem, Jerusalem

97239

Oregon Health Oregon Health & Sciences University-Knight Cancer Institute, Portland

6423906

Tel-Aviv Sourasky Medical Center, Tel Aviv